Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on MannKind (MNKD – Research Report), Vertex Pharmaceuticals (VRTX – Research Report) and Korro Bio (KRRO – Research Report).
MannKind (MNKD)
RBC Capital analyst Gregory Renza maintained a Hold rating on MannKind on April 4 and set a price target of $5.00. The company’s shares closed last Monday at $4.55.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
MannKind has an analyst consensus of Strong Buy, with a price target consensus of $7.00.
See Insiders’ Hot Stocks on TipRanks >>
Vertex Pharmaceuticals (VRTX)
In a report issued on April 4, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals, with a price target of $417.00. The company’s shares closed last Monday at $404.22.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of
Vertex Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $456.20.
Korro Bio (KRRO)
In a report issued on April 4, Luca Issi from RBC Capital maintained a Buy rating on Korro Bio, with a price target of $105.00. The company’s shares closed last Monday at $73.44.
According to TipRanks.com, Issi has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Korro Bio is a Strong Buy with an average price target of $130.00, which is a 93.9% upside from current levels. In a report issued on March 27, BMO Capital also maintained a Buy rating on the stock with a $120.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MNKD:
